Thoughtful discussion by Lisa Salvatore: Temab-A + Bev shows promise in mCRC, but haematological toxicity matters.

Evelyn Wong· @EvelynWongYT · X·2026-10-24 21:42· 19 小时前评分45

正文 · 原文

Thoughtful discussion by Lisa Salvatore: Temab-A + Bev shows promise in mCRC, but haematological toxicity matters.
Questions unanswered: What does Bev add? Can c-Met guide selection? What is the optimal dose? Awaiting Phase III validation #ESMO26 #ESMOAmbassadors @OncoAlert

23 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

1017P按 Developmental therapeutics 对上

Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors

https://esmocongress.esmo.org

NCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上

- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

https://esmocongress.esmo.org

来源：Evelyn Wong · x.com